Larimar Therapeutics (LRMR) Share-based Compensation (2013 - 2025)

Larimar Therapeutics' Share-based Compensation history runs 13 years deep, the most recent figure standing at $1.6 million for Q4 2025.

• Quarterly Share-based Compensation fell 81.31% year-over-year to $1.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $13.7 million (down 7.09% YoY) and the FY2025 annual result came in at $7.0 million, down 20.37% from the prior year.
• Share-based Compensation was $1.6 million for Q4 2025 at Larimar Therapeutics, down from $2.5 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $8.3 million in Q4 2024 and bottomed at $1.2 million in Q1 2021.
• A 5-year average of $2.2 million and a median of $1.8 million in 2023 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2021 — Share-based Compensation jumped 3968.97% — and 2025, when it plunged 81.31%.
• Larimar Therapeutics' Share-based Compensation stood at $1.5 million in 2021, then gained by 11.01% to $1.6 million in 2022, then grew by 16.74% to $1.9 million in 2023, then surged by 334.36% to $8.3 million in 2024, then sank by 81.31% to $1.6 million in 2025.
• Business Quant data shows LRMR's Share-based Compensation at $1.6 million in Q4 2025, $2.5 million in Q3 2025, and $1.8 million in Q2 2025.